Implications of Osteoblast-Osteoclast Interactions in the Management of Osteoporosis by Antiresorptive Agents Denosumab and Odanacatib

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Current Osteoporosis Reports

• Publication date

  2014-01-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s11914-014-0196-1PMID 24477416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit.

  2014cited by this paper
• Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation.

  2013cited by this paper
• Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.

  2013cited by this paper
• The Bone Resorption Inhibitors Odanacatib and Alendronate Affect Post-Osteoclastic Events Differently in Ovariectomized Rabbits

  2013cited by this paper
• Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity

  2013cited by this paper
• Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate.

  2013cited by this paper
• Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

  2013cited by this paper
• Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence

  2013cited by this paper
• Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.

  2013cited by this paper
• Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys

  2012cited by this paper
• Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

  2012cited by this paper
• Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.

  2012cited by this paper
• Potential role of odanacatib in the treatment of osteoporosis

  2012cited by this paper
• Effects of Odanacatib on Bone Mineralization Density Distribution in Thoracic Spine and Femora of Ovariectomized Adult Rhesus Monkeys: A Quantitative Backscattered Electron Imaging Study

  2012cited by this paper
• Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

  2012cited by this paper
• Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.

  2011cited by this paper
• Suppression of bone formation by osteoclastic expression of semaphorin 4D

  2011cited by this paper
• Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research

  2011cited by this paper
• Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys

  2011cited by this paper
• Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.

  2011cited by this paper
• Discontinuation of odanacatib and other osteoporosis treatments: Here today and gone tomorrow?

  2011cited by this paper
• Spotlight on Denosumab in Postmenopausal Osteoporosis

  2011cited by this paper
• Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys

  2011cited by this paper
• Cathepsin K inhibitors prevent bone loss in estrogen‐deficient rabbits

  2011cited by this paper
• Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

  2011cited by this paper
• Dissociation of Bone Resorption and Bone Formation in Adult Mice with a Non-Functional V-ATPase in Osteoclasts Leads to Increased Bone Strength

  2011cited by this paper
• Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research

  2011cited by this paper
• The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.

  2011cited by this paper
• Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone?

  2010cited by this paper
• Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect

  2010cited by this paper
• Specialized roles for cysteine cathepsins in health and disease.

  2010cited by this paper
• Heritable sclerosing bone disorders

  2010cited by this paper
• Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research

  2010cited by this paper
• Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

  2010cited by this paper
• Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double‐Blind, Randomized, Placebo‐Controlled Phase I Studies

  2009cited by this paper
• Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

  2009cited by this paper
• Treatment with a Potent Cathepsin K Inhibitor Preserves Cortical and Trabecular Bone Mass in Ovariectomized Monkeys

  2009cited by this paper
• TGF-β1-induced Migration of Bone Mesenchymal Stem Cells Couples Bone Resorption and Formation

  2009cited by this paper
• Bone density, strength, and formation in adult cathepsin K (-/-) mice.

  2009cited by this paper
• The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.

  2009cited by this paper
• The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.

  2009cited by this paper
• Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density

  2009cited by this paper
• Association Analysis of WNT10B With Bone Mass and Structure Among Individuals of African Ancestry

  2009cited by this paper
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• BMP-6 and mesenchymal stem cell differentiation.

  2009cited by this paper
• Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL

  2009cited by this paper
• The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

  2008cited by this paper
• Cardiotrophin‐1 Is an Osteoclast‐Derived Stimulus of Bone Formation Required for Normal Bone Remodeling

  2008cited by this paper
• Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

  2008cited by this paper
• Osteoclasts secrete non-bone derived signals that induce bone formation.

  2008cited by this paper
• Impaired growth plate function in bmp-6 null mice.

  2008cited by this paper
• Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate

  2008cited by this paper
• Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts.

  2008cited by this paper
• Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity?

  2007cited by this paper
• The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys

  2007cited by this paper
• Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

  2007cited by this paper
• Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

  2007cited by this paper
• Denosumab in postmenopausal women with low bone mineral density.

  2006cited by this paper
• Reduced osteoblastic population and defective mineralization in osteopetrotic (op/op) mice.

  2005cited by this paper
• Osteoclast-derived activity in the coupling of bone formation to resorption.

  2005cited by this paper
• Intracellular Machinery for Matrix Degradation in Bone‐Resorbing Osteoclasts

  2004cited by this paper
• Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis.

  2004cited by this paper
• Osteoclast Deficiency Results in Disorganized Matrix, Reduced Mineralization, and Abnormal Osteoblast Behavior in Developing Bone

  2004cited by this paper
• The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

  2003cited by this paper
• Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

  2003cited by this paper
• Osteoclast differentiation and activation

  2003cited by this paper
• Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure.

  2003cited by this paper
• The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.

  2003cited by this paper
• A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.

  2002cited by this paper
• In Vivo RANK Signaling Blockade Using the Receptor Activator of NF‐κB:Fc Effectively Prevents and Ameliorates Wear Debris‐Induced Osteolysis via Osteoclast Depletion Without Inhibiting Osteogenesis

  2002cited by this paper
• Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women.

  2002cited by this paper
• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

  2001cited by this paper
• Potent and Selective Inhibition of Human Cathepsin K Leads to Inhibition of Bone Resorption In Vivo in a Nonhuman Primate

  2001cited by this paper
• Osteoprotegerin mitigates tail suspension-induced osteopenia.

  2000cited by this paper
• Breast cancer cells interact with osteoblasts to support osteoclast formation.

  1999cited by this paper
• Localization of Rat Cathepsin K in Osteoclasts and Resorption Pits: Inhibition of Bone Resorption and Cathepsin K-Activity by Peptidyl Vinyl Sulfones

  1999cited by this paper
• RANK is essential for osteoclast and lymph node development.

  1999cited by this paper
• Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

  1999cited by this paper
• Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization

  1999cited by this paper
• Bisphosphonates: Pharmacology, Mechanisms of Action and Clinical Uses

  1999cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999cited by this paper
• Determination of Bone Markers in Pycnodysostosis: Effects of Cathepsin K Deficiency on Bone Matrix Degradation

  1999cited by this paper
• Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells.

  1998cited by this paper
• Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.

  1998cited by this paper
• The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases*

  1998cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur.

  1998cited by this paper
• Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency

  1996cited by this paper
• Osteopetrosis in the rat: coexistence of reductions in osteocalcin and bone resorption.

  1990cited by this paper
• Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration.

  1982cited by this paper
• Parathyroid hormone stimulates bone formation and resorption in organ culture: evidence for a coupling mechanism.

  1981cited by this paper
• Printed in U.S.A. Copyright © 1999 by The Endocrine Society Breast Cancer Cells Interact with Osteoblasts to Support

  year unknowncited by this paper
• Printed in U.S.A. Copyright © 2001 by The Endocrine Society OPG and PTH-(1–34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats

  year unknowncited by this paper

• Microfluidic ExoBONE Assay for Predicting Bone Mineral Density Improvement in Primary Hyperparathyroidism

  2025influential citation
• Bone augmentation with alloplastic graft material in a patient under bisphosphonate therapy: A case report and literature review.

  2024cites this paper
• Cross-sectional studies of the causal link between asthma and osteoporosis: insights from Mendelian randomization and bioinformatics analysis

  2024cites this paper
• Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases

  2024cites this paper
• Oxidative Stress and Natural Antioxidants in Osteoporosis: Novel Preventive and Therapeutic Approaches

  2023cites this paper
• Metal-organic Zn-zoledronic acid and 1-hydroxyethylidene-1,1-diphosphonic acid nanostick-mediated zinc phosphate hybrid coating on biodegradable Zn for osteoporotic fracture healing implants.

  2023cites this paper
• Inhibition of osteoclastogenesis after bisphosphonate therapy discontinuation: an in vitro approach

  2022cites this paper
• The Mechanism of Bone Remodeling After Bone Aging

  2022cites this paper
• The effect of osteoporosis treatment on bone mass.

  2022cites this paper
• 18F-Sodium Fluoride PET as a Diagnostic Modality for Metabolic, Autoimmune, and Osteogenic Bone Disorders: Cellular Mechanisms and Clinical Applications

  2021cites this paper
• Serpinb1a suppresses osteoclast formation

  2021cites this paper
• Bone remodeling biology

  2021cites this paper
• Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.

  2021cites this paper
• Corrosion and degradation decelerating alendronate embedded zinc phosphate hybrid coating on biodegradable Zn biomaterials

  2021cites this paper
• Circulating miR-122-5p and miR-375 as Potential Biomarkers for Bone Mass Recovery after Parathyroidectomy in Patients with Primary Hyperparathyroidism: A Proof-of-Concept Study

  2021cites this paper
• Osteoblast-Osteoclast Communication and Bone Homeostasis

  2020cites this paper
• High bone microarchitecture, strength, and resistance to bone loss in MRL/MpJ mice correlates with activation of different signaling pathways and systemic factors

  2020cites this paper
• Reprogrammed Epigenetic Landscape-Prophesied Functions of Bioactive Polysaccharides in Alleviating Diseases: A Pilot Study of DNA Methylome Remodeling in Astragalus Polysaccharide (APS)-Improved Osteoporosis in a Rat Model.

  2020cites this paper
• Cell Interaction and Mechanobiological Modeling of Bone Remodeling Process

  2020cites this paper
• A review on interventions to prevent osteoporosis and improve fracture healing in osteoporotic patients

  2020cites this paper
• The Cells of Bone and Their Interactions.

  2020cites this paper
• The novel role of Syndecan 3 in bone metabolism

  2019cites this paper
• Modulatory Effects of Plant Polyphenols on Bone Remodeling: A Prospective View From the Bench to Bedside

  2019cites this paper
• Cellular Processes by Which Osteoblasts and Osteocytes Control Bone Mineral Deposition and Maturation Revealed by Stage-Specific EphrinB2 Knockdown

  2019cites this paper
• The Coumarin Derivative 5′-Hydroxy Auraptene Suppresses Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways

  2019cites this paper
• Origin and Differentiation of Osteoclasts

  2019cites this paper
• Exploration of effect of Odanacatib on inhibiting orthodontic recurrence in rats and on CatK and IGF-1 mRNA.

  2019cites this paper
• Perfil biométrico, histomorfométrico e bioquímico no tratamento com atorvastatina cálcica de ratas com osteoporose induzida com dexametasona

  2018cites this paper
• Association Between Marginal Jawbone Loss and Onset of Rheumatoid Arthritis and Relationship to Plasma Levels of RANKL

  2018cites this paper
• Dual modulation of bone formation and resorption with zoledronic acid-loaded biodegradable magnesium alloy implants improves osteoporotic fracture healing: An in vitro and in vivo study.

  2018cites this paper
• Coupling factors and exosomal packaging microRNAs involved in the regulation of bone remodelling

  2018cites this paper
• Effects of Lectin (ScLL) on osteoclast‐like multinucleated giant cells’ maturation—A preliminary in vitro study

  2018cites this paper
• Differing Effects of Parathyroid Hormone, Alendronate, and Odanacatib on Bone Formation and on the Mineralization Process in Intracortical and Endocortical Bone of Ovariectomized Rabbits

  2018cites this paper
• Asiaticoside, a component of Centella asiatica attenuates RANKL‐induced osteoclastogenesis via NFATc1 and NF‐κB signaling pathways

  2018cites this paper
• Biometric, histomorphometric, and biochemical profile in atorvastatin calcium treatment of female rats with dexamethasone-induced osteoporosis

  2018cites this paper
• Cathepsin K inhibition preserves compressive load in lumbar vertebrae of osteoporotic monkeys

  2018cites this paper
• Anabolic Therapies in Osteoporosis and Bone Regeneration

  2018cites this paper
• Effects of Parathyroid Hormone, Alendronate and Odanacatib on the mineralisation process in intracortical and endocortical Haversian bone of ovariectomized rabbits

  2018cites this paper
• This is a repository copy of Severe Compromise of Preosteoblasts in a Surgical Mouse Model of Bisphosphonate-Associated Osteonecrosis of the Jaw.

  2018influential citation
• Association Between Marginal Jawbone Loss and Onset of Rheumatoid Arthritis and Relationship to Plasma Levels of RANKL

  2017cites this paper
• Determining If Lowering the Level of Dietary Calcium and Vitamin D in AIN-93G Diet Supports Normal Bone Development and Intestinal Integrity in Female CD-1 Mice

  2017cites this paper
• Multiple Vertebral Osteonecroses (Kümmell’s Disease) After 10 Years on Denosumab: Is Osteocyte Apoptosis to Blame?

  2017cites this paper
• G protein‐coupled receptors as anabolic drug targets in osteoporosis

  2017cites this paper
• Childhood cancer chemotherapy–induced bone damage: pathobiology and protective effects of resveratrol and other nutraceuticals

  2017cites this paper
• The Multifaceted Osteoclast; Far and Beyond Bone Resorption

  2016cites this paper
• New therapies in osteoporosis

  2016cites this paper
• Nuevas terapias en osteoporosis

  2016cites this paper
• Investigating the effects of downstream parathyroid hormone (PTH) targets on bone strength and quality

  2016cites this paper
• Coupling: The Influences of Immune and Bone Cells

  2016cites this paper
• A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K

  2016cites this paper
• Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw.

  2016influential citation
• Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study

  2016cites this paper
• Elucidating Vacuolar H+-ATPase Subunit Interactions: A Systematic Structural Analysis

  2015cites this paper
• Coupling Signals between the Osteoclast and Osteoblast: How are Messages Transmitted between These Temporary Visitors to the Bone Surface?

  2015cites this paper
• The effect of cathepsin K inhibitor on osteoclastic activity compared to alendronate and enamel matrix protein.

  2015cites this paper
• Is RANKL inhibition both anti-resorptive and anabolic in rheumatoid arthritis?

  2015cites this paper
• Osteoclast Deficiency Contributes to Temporomandibular Joint Ankylosed Bone Mass Formation

  2015cites this paper
• Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.

  2014cites this paper
• Salvia miltiorrhiza: an ancient Chinese herbal medicine as a source for anti-osteoporotic drugs.

  2014cites this paper
• Regulation of cortical and trabecular bone mass by communication between osteoblasts, osteocytes and osteoclasts.

  2014cites this paper
• This item is the archived peer-reviewed author-version of: Sclerosing bone dysplasias : leads toward novel osteoporosis treatments

  year unknowncites this paper